{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Protein Tyrosine Kinase/PTK > PF-02341066 HydrochlorideCAS：1415560-69-8
Molecular Formula：C21H23Cl3FN5O
Molecular Weight：486.8
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：Solid
Qty：
Size：
| CAS | 1415560-69-8 |
| Name | PF-02341066 Hydrochloride |
| Molecular Formula | C21H23Cl3FN5O |
| Molecular Weight | 486.8 |
| Solubility | Soluble in DMSO ≥5mg/mL(Need ultrasonic) |
| Purity | ≥98% |
| Appearance | Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| MDL | MFCD23378578 |
| SMILES | C[C@H](C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N.Cl |
| InChIKey | BTDNHKQCPIBABF-UTONKHPSSA-N |
| InChI | InChI=1S/C21H22Cl2FN5O.ClH/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15;/h2-3，8-12，15，26H，4-7H2，1H3，(H2，25，27);1H/t12-;/m1./s1 |
| PubChem CID | 71576688 |
| Target Point | c-Met;ALK;ROS1 |
| Passage | Protein Tyrosine Kinase/RTK |
| Background | PF-02341066 Hydrochloride is a selective ATP-competitive biAlk and c-Met inhibitor. It is also a ROS proto-oncogene 1 (ROS1) inhibitor， which has effective tumor growth inhibition effect. |
| Biological Activity | Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable， selective， and ATP-competitive dual ALK and c-Met inhibitor with IC50s of 20 and 8 nM， respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays， respectively. It is also a ROS proto-oncogene 1 (ROS1) inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition.[1-4] |
| IC50 | IC50: 20 nM (ALK)， 8 nM (c-Met)[3] |
| Data Literature Source | [1]. Zou HY， et al. An orally available small-molecule inhibitor of c-Met， PF-2341066， exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007， 67(9)， 4408-4417. [2]. Christensen JG， et al. Cytoreductive antitumor activity of PF-2341066， a novel inhibitor of anaplastic lymphoma kinase and c-Met， in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007， 6(12 Pt 1)， 3314-3322. [3]. Cui JJ， et al. Structure based drug design of crizotinib (PF-02341066)， a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011 Sep 22;54(18):6342-63. [4]. Cullinane C， et al. Differential (18)F-FDG and 3-deoxy-3-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models. J Nucl Med. 2011 Aug;52(8):1261-7 |
| Unit | Bottle |
| Specification | 10mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
